Cost-effectiveness of different strategies for diagnosis of deep vein thrombosis

被引：0
|
作者：
Patel, V. A. [1 ]
McGhan, W. F. [1 ]
机构：
[1] Allegheny Univ Hlth Sci, Philadelphia, PA 19102 USA
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)70619-7
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A195 / A195
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness Analysis of AngioJet and CDT for Lower Extremity Deep Vein Thrombosis Among Chinese Population
    Li, Guanqiang
    Xu, Miao
    Xu, Zhouqian
    Sun, Yuan
    Zhang, Jingbo
    Zhang, Xicheng
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2021, 27
  • [32] Cost-effectiveness analysis of dalteparin in prolonged prophylaxis against deep vein thrombosis after hip arthroplasty
    Segú, JL
    Soto, J
    VALUE IN HEALTH, 2003, 6 (06) : 649 - 649
  • [33] COST-EFFECTIVENESS OF RIVAROXABAN COMPARED WITH ENOXAPARIN PLUS WARFARIN FOR THE TREATMENT OF ACUTE DEEP VEIN THROMBOSIS IN CHINA
    Yang, L.
    Wu, J.
    VALUE IN HEALTH, 2018, 21 : S62 - S63
  • [34] A COST-EFFECTIVENESS ANALYSIS OF PROPHYLAXIS AGAINST DEEP-VEIN THROMBOSIS IN MAJOR ORTHOPEDIC-SURGERY
    OSTER, G
    TUDEN, RL
    COLDITZ, GA
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 257 (02): : 203 - 208
  • [35] Fondaparinux for Isolated Superficial Vein Thrombosis of the Legs A Cost-Effectiveness Analysis
    Blondon, Marc
    Righini, Marc
    Bounameaux, Henri
    Veenstra, David L.
    CHEST, 2012, 141 (02) : 321 - 329
  • [36] Cost-effectiveness and sensitivity of screening strategies for hepatocellular carcinoma and portal vein thrombosis in liver transplant candidates.
    Brown, KA
    Thomas, MR
    Moonka, DK
    Ben-Menachem, T
    Nakhleh, RE
    Abouljoud, MA
    HEPATOLOGY, 1999, 30 (04) : 665A - 665A
  • [37] Cost-effectiveness and sensitivity of screeing strategies for hepatocellular carcinoma and portal vein thrombosis in liver transplant candidates.
    Brown, KA
    Thomas, M
    Nakhleh, R
    Abouljoud, M
    Moonka, D
    TRANSPLANTATION, 2000, 69 (08) : S390 - S390
  • [38] COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE FOR THE SECONDARY PREVENTION OF RECURRENT DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN THE UNITED KINGDOM
    Wolowacz, S.
    Brockbank, J.
    Sunderland, T. J.
    Gonschior, A. K.
    VALUE IN HEALTH, 2013, 16 (07) : A526 - A526
  • [39] Cost Effectiveness of the Prevention and Treatment of Deep Vein Thrombosis and Pulmonary Embolism
    David R. Anderson
    Bernie J. O’Brien
    PharmacoEconomics, 1997, 12 : 17 - 29
  • [40] Cost-effectiveness of rivaroxaban compared with enoxaparin plus warfarin for the treatment of hospitalised acute deep vein thrombosis in China
    Yang, Li
    Wu, Jingjing
    BMJ OPEN, 2020, 10 (07):
12345